Crossmark

B cell therapy in ANCA-associated vasculitis: current and emerging treatment options

Crossref DOI link: https://doi.org/10.1038/s41584-018-0065-x

Published Online: 2018-08-14

Published Print: 2018-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

McClure, Mark

Gopaluni, Seerapani

Jayne, David

Jones, Rachel
License Information

Text and Data Mining valid from 2018-08-14
More Information

Article History

First Online: 14 August 2018

Change Date: 2 November 2018

Change Type: Correction

Change Details: In the section ‘Combining B cell-targeted therapies’ in the originally published version of this article, the 24-week interim analysis for the CALIBRATE study was incorrectly given as the 2- to 4-week interim analysis. This error has now been corrected in the HTML and PDF versions of the manuscript.

Competing interests

: R.J. and D.J. declare that they have received financial support in the form of a grant from GlaxoSmithKline and the Medical Research Council towards an experimental medicine study evaluating the biological effects of combination therapy with rituximab and belimumab in anti-neutrophil cytoplasmic antibody-associated vasculitis. The other authors declare no competing interests.